Can I Take Zinc with Jardiance?

What Jardiance (Empagliflozin) Actually Does

Jardiance is FDA-approved for glycemic control in type 2 diabetes, to reduce cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, to reduce hospitalization for heart failure, and to slow eGFR decline in chronic kidney disease (CKD) [1]. The drug blocks sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, preventing reabsorption of roughly 60 to 90 grams of glucose per day and excreting it in urine [2].

The EMPA-REG OUTCOME Trial

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg daily reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% versus placebo (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [3]. Cardiovascular death specifically fell by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) [3]. These findings changed how clinicians view SGLT2 inhibitors beyond glucose lowering alone.

Renal Outcomes and the EMPA-KIDNEY Trial

The EMPA-KIDNEY trial (N=6,609) showed that empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% compared with placebo (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) [4]. The FDA subsequently expanded the label indication to include CKD in 2023 [1].

Because Jardiance works through the kidney, anything that alters renal handling of minerals, including zinc, becomes a legitimate clinical question.

Zinc Basics: What It Does and Why It Matters in Metabolic Disease

Zinc is an essential trace mineral. The body contains roughly 2 to 3 grams total, stored predominantly in muscle and bone [5]. Adults need 8 mg per day (women) or 11 mg per day (men) from diet and supplements combined, and the Tolerable Upper Intake Level (UL) set by the National Institutes of Health is 40 mg of elemental zinc per day [5].

Zinc as an Insulin Cofactor

Zinc plays a direct role in glucose metabolism. Beta cells in the pancreas use zinc to crystallize and store insulin; each insulin hexamer contains two zinc ions [6]. Low zinc status is associated with impaired insulin secretion, and multiple cross-sectional studies link zinc deficiency with higher fasting glucose [6]. A meta-analysis published in Diabetes Research and Clinical Practice (2015, 39 trials, N=1,946) found that zinc supplementation significantly reduced fasting blood glucose (weighted mean difference: -14.15 mg/dL, P<0.001) and HbA1c (-0.54%, P<0.001) in people with type 2 diabetes [7].

Zinc and Insulin Resistance

Beyond secretion, zinc activates insulin receptor signaling and acts as a mimetic of insulin in adipocytes at pharmacologic concentrations [6]. Animal models show that zinc-deficient diets worsen insulin resistance within weeks, though human intervention data are more mixed [6].

Dietary Sources vs. Supplement Forms

Oysters contain more zinc per serving than any other food (74 mg per 3-oz serving). Red meat, poultry, beans, nuts, and fortified cereals are also substantial sources [5]. Supplement forms vary in elemental zinc content: zinc gluconate (14.3% elemental), zinc citrate (31% elemental), and zinc sulfate (23% elemental). When a label says "50 mg zinc gluconate," the elemental zinc is approximately 7 mg. Reading labels accurately matters because over-the-counter products often list the salt weight, not elemental zinc.

The Core Question: Does Zinc Interact Directly with Empagliflozin?

No published pharmacokinetic study has examined zinc co-administration with empagliflozin directly. The FDA prescribing information for Jardiance does not list zinc as a known interaction [1]. Natural Medicines Database (formerly Natural Standard) classifies the interaction between zinc and SGLT2 inhibitors as not established in the published literature as of 2024.

That absence of evidence is not the same as evidence of absence. Three indirect mechanisms deserve attention.

Mechanism 1: Additive Glycemic Effect

Both empagliflozin and zinc supplementation may lower fasting blood glucose. Empagliflozin reduces HbA1c by approximately 0.5 to 0.8 percentage points at standard doses [2]. The 2015 meta-analysis noted above found zinc reduced HbA1c by 0.54% in patients with type 2 diabetes [7]. Taken together, the additive effect is probably beneficial for most patients, but those already at target HbA1c could theoretically experience increased hypoglycemia risk, particularly if they also take sulfonylureas or insulin. SGLT2 inhibitors alone carry a low intrinsic hypoglycemia risk because their glucose-lowering effect is glucose-dependent, but combination regimens change that calculation.

Mechanism 2: Urinary Zinc Excretion and SGLT2 Inhibition

SGLT2 inhibitors increase urinary glucose output substantially. Some researchers have proposed that osmotic diuresis associated with SGLT2 inhibition could also increase urinary excretion of trace minerals including zinc [8]. A 2021 study in Biological Trace Element Research examined serum zinc in 60 patients with type 2 diabetes before and after 12 weeks of dapagliflozin (another SGLT2 inhibitor) at 10 mg/day and found no statistically significant change in serum zinc (P=0.38) [8]. Empagliflozin data specifically are not yet available in the published literature, but the mechanism suggests careful monitoring is reasonable rather than supplementation being automatically contraindicated.

Mechanism 3: Copper Depletion Above the UL

Zinc and copper compete for absorption via metallothionein in intestinal enterocytes [9]. Chronic zinc supplementation above 40 mg of elemental zinc per day reduces copper absorption and may cause copper deficiency over months to years [9]. Copper deficiency causes anemia, neutropenia, and neurological complications, any of which would confound the management of someone taking Jardiance for diabetes or heart failure [9]. The National Institutes of Health Office of Dietary Supplements notes this interaction explicitly [5].

Patients who take high-dose zinc for immune support (50 to 100 mg elemental zinc per day, as seen in some over-the-counter cold products and online "immune stacks") while also taking Jardiance deserve copper monitoring with a complete blood count every 6 to 12 months.

Pharmacokinetics of Empagliflozin: Where Zinc Could or Could Not Interfere

Empagliflozin is absorbed rapidly with a Tmax of approximately 1.5 hours. It is not significantly metabolized by CYP450 enzymes; primary elimination is via glucuronidation by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with approximately 41% excreted in urine and 51% in feces [2]. Zinc does not meaningfully inhibit or induce UGT enzymes at physiologic or supplemental concentrations [10].

Zinc's own absorption in the gut occurs primarily in the jejunum via ZIP4 transporters and is separate from the transporter systems empagliflozin uses [9]. No chelation interaction occurs between zinc and empagliflozin under gastrointestinal pH conditions. These two agents can be taken at the same time from a pharmacokinetic standpoint.

Monitoring Recommendations When Taking Both

The following framework applies to patients taking empagliflozin who want to add zinc supplementation, or who are already taking zinc at any dose.

Baseline Labs Before Starting Zinc

• Serum zinc (reference range: 70 to 120 mcg/dL in most labs)
• Serum copper (reference range: 70 to 140 mcg/dL)
• Complete blood count (CBC) to screen for anemia or neutropenia
• Basic metabolic panel including eGFR and serum creatinine (already standard on Jardiance)
• HbA1c

Dose Thresholds That Change the Risk Profile

At 8 to 25 mg elemental zinc per day, risk from copper depletion or additive hypoglycemia is low. Most patients in this range do not need additional monitoring beyond their standard Jardiance follow-up.

At 26 to 40 mg elemental zinc per day, the patient is approaching or at the UL. Checking serum copper at 3 months is reasonable, especially if the patient is also on a low-copper diet.

Above 40 mg elemental zinc per day, copper depletion risk becomes clinically relevant. The American Academy of Family Physicians recommends against routine supplementation at doses that exceed the UL without documented deficiency [11]. If a prescriber approves high-dose zinc for a specific indication, CBC and serum copper monitoring every 3 to 6 months is appropriate.

Follow-Up Labs at 3 Months

• Repeat HbA1c if zinc dose is above 25 mg elemental zinc per day, given the potential additive glucose-lowering effect [7]
• Serum copper if zinc dose exceeds 40 mg elemental zinc per day [5]
• Renal function panel if the patient has CKD, since empagliflozin's renal protective effect interacts with mineral handling broadly [4]

What Patients Should Tell Their Prescriber

Open disclosure of all supplements is standard of care. The 2023 American Diabetes Association Standards of Care in Diabetes state: "Patients should be asked about the use of over-the-counter medications, dietary supplements, and complementary medicines, as these may affect glycemia or interact with prescribed medications" [12]. This applies directly to zinc.

Your prescriber needs to know:

• The brand name and full label dose of the zinc product (remember: label weight vs. Elemental zinc differ)
• Whether you are taking a multivitamin that also contains zinc, which compounds total daily intake
• Any other supplements in your regimen that contain copper, since some formulations combine zinc with copper specifically to prevent depletion

Special Populations: CKD, Heart Failure, and Older Adults

CKD Patients on Jardiance

Patients with CKD (eGFR 20 to 45 mL/min/1.73m², the range where Jardiance is now used per the expanded label [1]) may already have altered zinc and trace mineral metabolism. A 2020 review in Nutrients found that zinc deficiency is present in 30 to 50% of patients with stage 3 to 5 CKD due to reduced dietary intake, impaired intestinal absorption, and increased dialysis losses [13]. In this population, modest zinc supplementation (8 to 15 mg elemental zinc per day) may actually correct deficiency rather than add surplus, which changes the risk-benefit calculus substantially.

Heart Failure Patients

Empagliflozin is approved to reduce hospitalizations for heart failure with reduced ejection fraction following the EMPEROR-Reduced trial (N=3,730; HR for cardiovascular death or hospitalization for heart failure 0.75, 95% CI 0.65 to 0.86, P<0.001) [14]. Heart failure patients often have micronutrient deficiencies. A 2022 paper in the European Journal of Heart Failure described zinc deficiency in approximately 26% of ambulatory heart failure patients and associated it with worse functional class [15]. Addressing documented zinc deficiency in this group is medically justified, and the absence of a direct interaction with empagliflozin means it need not be withheld.

Older Adults

Zinc absorption decreases with age. Adults over 60 absorb roughly 20 to 30% less dietary zinc than younger adults [5]. Many older adults taking Jardiance for type 2 diabetes or CKD may be subtly zinc-deficient without knowing it. A serum zinc level costs under $30 in most lab settings and provides actionable information before supplementation begins.

Practical Dosing Guidance

For adults without documented zinc deficiency who want general immune or metabolic support while taking Jardiance, a dose of 8 to 15 mg of elemental zinc per day from a single supplement (not counting dietary intake) is reasonable and stays well below the 40 mg UL [5].

For adults with documented zinc deficiency (serum zinc <70 mcg/dL), therapeutic repletion is typically 25 to 50 mg elemental zinc per day for 3 to 6 months under clinical supervision, with copper monitoring [9]. The prescriber managing Jardiance therapy should be aware of this repletion course.

Cold-lozenges containing zinc acetate (typically 13.3 mg elemental zinc per lozenge, taken every 2 hours) provide a very short-term, high daily dose. Total daily zinc from lozenge protocols can reach 100 mg elemental zinc or more. Short-term use (fewer than 7 days) is unlikely to cause copper depletion, but this dose combined with ongoing Jardiance therapy still warrants disclosure to the care team if cold lozenge use becomes a regular habit.

Drug-Supplement Interaction Summary Table

| Factor | Empagliflozin (Jardiance) | Zinc Supplement | Combined Consideration | |---|---|---|---| | Pharmacokinetic interaction | Not metabolized by CYP450 | Absorbed via ZIP4 in jejunum | No chelation or enzyme interaction | | Glucose effect | Lowers HbA1c 0.5 to 0.8% | May lower HbA1c up to 0.54% [7] | Monitor HbA1c if zinc above 25 mg elemental | | Renal effect | Reduces eGFR decline [4] | Excreted renally; may increase in CKD deficiency [13] | Check eGFR at baseline and 3 months | | Mineral balance | May modestly increase urinary zinc [8] | Competes with copper above 40 mg/day [5] | Monitor copper if zinc exceeds UL | | Hypoglycemia risk | Low intrinsic risk | Mild additive effect | Higher risk if combined with sulfonylurea or insulin |

What the Evidence Does Not Yet Cover

No randomized controlled trial has specifically studied empagliflozin co-administration with zinc supplementation as a primary endpoint. The interaction data available come from mechanistic studies, separate zinc diabetes trials, SGLT2 inhibitor trace mineral studies (most using dapagliflozin rather than empagliflozin), and pharmacokinetic first-principles [2, 6, 7, 8]. A well-designed 24-week RCT examining zinc status, copper status, and glycemic markers in empagliflozin-treated patients with type 2 diabetes would meaningfully close this evidence gap. Until that trial exists, clinical guidance relies on indirect data plus standard supplement safety principles.